SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 67 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $413,000 | -57.6% | 429,013 | -47.6% | 0.00% | -100.0% |
| Q1 2022 | $975,000 | +3.6% | 818,962 | +844.6% | 0.00% | 0.0% |
| Q4 2020 | $941,000 | +51.5% | 86,700 | +48.7% | 0.00% | 0.0% |
| Q2 2020 | $621,000 | -30.4% | 58,300 | -54.8% | 0.00% | 0.0% |
| Q4 2019 | $892,000 | -70.0% | 129,085 | -55.0% | 0.00% | -66.7% |
| Q3 2019 | $2,975,000 | +8.0% | 286,600 | -3.6% | 0.00% | +50.0% |
| Q2 2019 | $2,754,000 | +36.7% | 297,400 | +34.9% | 0.00% | 0.0% |
| Q1 2019 | $2,015,000 | +189.9% | 220,500 | +76.8% | 0.00% | +100.0% |
| Q4 2018 | $695,000 | +106.2% | 124,700 | +340.6% | 0.00% | – |
| Q3 2018 | $337,000 | -80.0% | 28,300 | -82.8% | 0.00% | -100.0% |
| Q2 2018 | $1,684,000 | +58.4% | 164,900 | +128.4% | 0.00% | 0.0% |
| Q3 2017 | $1,063,000 | +144.9% | 72,200 | +167.4% | 0.00% | 0.0% |
| Q2 2017 | $434,000 | – | 27,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 4,806,656 | $58,449,000 | 19.02% |
| Casdin Capital, LLC | 182,141 | $2,215,000 | 1.83% |
| Aisling Capital LLC | 508,565 | $6,184,000 | 1.44% |
| Redmile Group, LLC | 948,440 | $11,533,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,812,778 | $22,043,000 | 0.91% |
| EcoR1 Capital, LLC | 63,596 | $773,000 | 0.25% |
| Eventide Asset Management | 150,000 | $1,824,000 | 0.12% |
| AWM Investment Company, Inc. | 47,550 | $578,000 | 0.11% |
| Weiss Multi-Strategy Advisers LLC | 49,000 | $596,000 | 0.03% |
| Baker Brothers Advisors | 204,465 | $2,486,000 | 0.02% |